Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459461 | 0.79 | KMT2A (0.63) | LMNAKMT2AHTTPOLBNPSR1 | |
| SCHEMBL4212064 | 0.78 | GAA (0.72) | LMNAGLAKMT2ANPSR1HPGD | |
| SCHEMBL1563031 | 0.77 | KMT2A (0.70) | KMT2AHTTMAPTALDH1A1TSHR | |
| SCHEMBL12459463 | 0.77 | CYP3A4 (0.67) | LMNAGLAKMT2AHTTALDH1A1 | |
| SCHEMBL13832073 | 0.75 | MEN1 (0.69) | LMNAGLAKMT2AHTTNPSR1 | |
| SCHEMBL13381602 | 0.74 | KMT2A (0.76) | LMNAKMT2AHTTPOLBNPSR1 | |
| SCHEMBL11996353 | 0.74 | MAPT (0.62) | LMNAGLAKMT2AHTTPOLB | |
| SCHEMBL12459696 | 0.74 | CYP3A4 (0.63) | LMNAKMT2AHTTALDH1A1TSHR | |
| SCHEMBL13831958 | 0.73 | CYP3A4 (0.65) | LMNAKMT2AHTTALDH1A1TSHR | |
| SCHEMBL13831273 | 0.72 | NPSR1 (0.69) | LMNAKMT2AHTTPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2353593-A1 | Non-nucleoside reverse transcriptase inhibitors | Ardea Biosciences, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, TYMP, RNGTT | LMNA 1811/4885GLA 739/4885KMT2A 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.